Vitamin B12

Vitamin B12, also called cobalamin, is a water-soluble micronutrient built around a cobalt-containing corrin ring. It acts as a coenzyme for enzymes involved in DNA synthesis, methylation, and mitochondrial metabolism. Only certain bacteria and archaea can produce it, so humans and other animals must obtain it from their diet or from microbial sources in their environment. Because it is needed for blood cell formation and for maintaining the nervous system, a shortage can produce anemia and nerve damage.

The vitamin's importance is also reflected in the history of medicine. Its story spans more than a century, from the clinical description of pernicious anemia to the identification of the vitamin and the mapping of its role in metabolism. The work was recognized by two Nobel Prizes: one in Physiology or Medicine for the liver-based treatment of pernicious anemia, and one in Chemistry for the crystallographic determination of the molecule's structure.

This entry covers the chemistry and forms of vitamin B12, its two known enzymatic roles, how it is absorbed, transported, and stored, its dietary and microbial sources, and the history of its discovery. It then describes the causes and clinical features of deficiency, the diagnostic markers used to assess status, the populations most affected, and approaches to clinical management. It concludes with unresolved questions, including the debate over diagnostic cut-offs and the clinical significance of subclinical deficiency.

Chemical structure and forms

The corrin ring and the central cobalt ion

Vitamin B12 is built around a corrin ring, a large macrocycle made of four modified pyrrole units. The ring holds a single cobalt ion at its centre, and four of the cobalt's six coordination sites are occupied by nitrogen atoms from the ring. The lower (α) site is taken by a nitrogen of 5,6-dimethylbenzimidazole, a base that is tethered back to the ring through a sugar and phosphate unit and a side chain. The upper (β) site is the variable position, and its occupant determines which form of the vitamin a molecule belongs to. The corrin ring is related to the porphyrin rings of hemoglobin and chlorophyll, but it lacks one of the bridging carbon atoms, so it is less planar and less fully conjugated. The molecule is large, with a molecular mass of roughly 1,300 to 1,500 daltons, and it is generally regarded as the most structurally complex vitamin.

The three-dimensional structure was worked out by X-ray crystallography in the laboratory of Dorothy Hodgkin in the 1950s, and her work was recognised by the 1964 Nobel Prize in Chemistry. Because the cobalt sits inside the ring, the vitamin is often described as a coordination complex of cobalt, the only metal in the molecule.

The cobalamin family and the Co–C bond

"Cobalamin" is the generic name for the group of compounds that share this corrin-cobalt core and differ only in the upper ligand. The family is therefore defined by the shared core rather than by any single bond. The cobalt–carbon bond is found only in the two coenzyme forms, in which the upper ligand is a carbon-bearing group. This bond is the reactive centre of those forms: in methylcobalamin the cobalt holds a methyl group that can be transferred to another molecule, and in adenosylcobalamin the bond can break homolytically, generating a radical on the 5′-deoxyadenosyl group.

Named forms and their origins

Cyanocobalamin is the name used for the vitamin in older literature and in most supplements and fortified foods. Its upper ligand is a cyano group, and it was the form first obtained when the vitamin was isolated from liver in 1948. Subsequent work showed that the cyano group is largely an artefact of the isolation procedure, because cyanide was used during purification and the group is not the natural upper ligand. Hydroxocobalamin, with a hydroxyl group at the upper site, is the form that occurs naturally alongside the two coenzyme forms.

Methylcobalamin carries a methyl group at the upper site and acts as the coenzyme for methionine synthase in the cytoplasm. Adenosylcobalamin carries a 5′-deoxyadenosyl group and serves as the coenzyme for methylmalonyl-CoA mutase in mitochondria. These two cofactor forms are the ones that the enzymes use directly.

Which forms are biologically active

The statement that only certain forms are active needs qualification. Enzymes accept only the methyl and adenosyl forms, but cyanocobalamin and hydroxocobalamin are not inert. Once inside cells, the upper ligand can be interchanged, so the various forms can be converted into adenosyl-, hydroxo- or methylcobalamin according to cellular demand. The upper ligand is therefore better understood as a variable that governs the chemistry of the coenzyme forms, not as a switch that decides whether the vitamin works at all.

The lower ligand also has a functional role. In methionine synthase, the dimethylbenzimidazole group is displaced from the cobalt by a histidine residue of the enzyme, a configuration that places the cobalt in a more reactive state. A similar arrangement is seen in adenosylcobalamin bound to methylmalonyl-CoA mutase. Because the enzyme controls the lower ligand as well as the upper one, the protein environment is as important as the side chain in determining whether a given form of the molecule can act as a coenzyme.

Sources consulted for this section: Genetic disorders of vitamin B12 metabolism (Expert Reviews in Molecular Medicine) | https://www.cambridge.org/core/journals/expert-reviews-in-molecular-medicine/article/genetic-disorders-of-vitamin-b12-metabolism-eight-complementation-groups-eight-genes/F2332EED37ECD12E8216D98716A7E442 ; Vitamin B12, University of Bristol | https://www.chm.bris.ac.uk/motm/vitb12/b12.htm ; Biological properties of vitamin B12 (Nutrition Research Reviews) | https://www.cambridge.org/core/journals/nutrition-research-reviews/article/biological-properties-of-vitamin-b12/58C586B5D6B9960C421D92A41D7D0691 ; Vitamin B12: Cobalamin (Chemistry LibreTexts) | https://chem.libretexts.org/Bookshelves/Biological_Chemistry/Supplemental_Modules_(Biological_Chemistry)/Vitamins_Cofactors_and_Coenzymes/Vitamin_B:_Cobalamin ; Cyanocobalamin overview (ScienceDirect) | https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/cyanocobalamin ; US patent 6004533 (cobalamin nomenclature and forms) | https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6004533

Biochemical functions

Vitamin B12 acts in humans as a cofactor for only two enzymes. Methionine synthase, which is located in the cytosol, uses methylcobalamin as a carrier of methyl groups. It moves a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine and tetrahydrofolate. During the reaction the cobalamin alternates between its methylated form and a reduced cob(I)alamin state, so the cofactor is regenerated in each cycle. The enzyme also needs periodic repair: an inactive form is restored by a dedicated reductase that uses NADPH as electron donor and S-adenosylmethionine as methyl donor. This reactivation step is one reason the enzyme's activity depends on a steady supply of the vitamin and of enzyme partners rather than on the vitamin alone.

The second enzyme, methylmalonyl-CoA mutase, works inside the mitochondria and uses the adenosylated form of the cofactor. It catalyses a 1,2 rearrangement that converts methylmalonyl-CoA into succinyl-CoA. Methylmalonyl-CoA arises when the body breaks down certain branched-chain amino acids, cholesterol, and odd-chain fatty acids. Succinyl-CoA then enters the citric acid cycle, so this reaction links the vitamin to energy metabolism. Because the adenosylcobalamin must be loaded onto the mutase and later released, the reaction depends on a set of intracellular chaperone proteins that process and deliver the cofactor. Defects in this trafficking pathway, rather than in the vitamin itself, can therefore impair both enzymes.

The two reactions are connected through folate metabolism. Methionine synthase is the only route by which the methyl group carried by 5-methyltetrahydrofolate is returned to the folate pool as tetrahydrofolate. When B12 is short, folate becomes trapped in the methylated form, and the cell has less free tetrahydrofolate available as a one-carbon carrier. Tetrahydrofolate derivatives are needed to build the purine rings and to make thymidylate, a precursor of thymine in DNA. Impaired synthesis of these building blocks slows nuclear division, which is consistent with the megaloblastic changes seen in the blood-forming tissues. The same coupling explains why the synthesis of DNA and RNA is affected even though neither B12-dependent enzyme sits directly in those pathways. This account is widely used to explain deficiency, though the full mechanism remains a subject of study.

Methionine is a precursor of S-adenosylmethionine, the principal methyl donor in the cell. Through this molecule, B12 status influences the methylation of DNA, RNA, proteins, and lipids, and so affects gene regulation and many other cellular processes. Efficient methylation of the DNA and of other macromolecules is one route by which the vitamin shapes the activity of genes. Methylation is also needed for the normal production of myelin, the lipid sheath that wraps nerve fibres in the central nervous system and the peripheral nervous system. Myelin synthesis and repair appear to depend on this methyl-donor supply.

Impaired myelin formation may also have a second, separate cause. The proposed mechanism is that accumulation of methylmalonyl-CoA leads to the incorporation of abnormal odd-chain fatty acids into membrane lipids, and this may weaken the structure of myelin. Together with the methylation defect, this offers one explanation for the neurological damage seen in B12 deficiency, which can progress even when blood counts look normal. These pathways are an active area of biochemical research, and the relative contribution of each route to neurological disease is not fully established.

Absorption, transport and storage

Absorption of dietary cobalamin begins in the stomach. In food, B12 is bound to proteins, and gastric acid and pepsin release it so that it can associate with haptocorrin, a binding protein in saliva and gastric secretions. In the duodenum, pancreatic proteases digest haptocorrin and free the vitamin, which then binds intrinsic factor, a glycoprotein secreted by gastric parietal cells. The intrinsic factor–B12 complex resists further digestion and travels to the terminal ileum, where a specific receptor complex recognizes it and mediates its uptake into enterocytes.

Intrinsic factor-mediated absorption is saturable, so it can handle only a limited amount of B12 at a time, roughly on the order of a few micrograms per dose. A small fraction of any oral dose, about 1%, crosses the gut wall by passive diffusion without intrinsic factor. This route is the reason high-dose oral supplements can still deliver useful amounts of the vitamin, even in people whose intrinsic factor production is inadequate.

After uptake, B12 enters the bloodstream bound to plasma proteins. The transcobalamin proteins carry it in different ways. Transcobalamin II is the only carrier that delivers B12 to peripheral tissues, where cells take up the transcobalamin II–B12 complex through a dedicated cell-surface receptor. Haptocorrin, sometimes called transcobalamin I, binds the majority of the circulating vitamin, but much of this bound pool is not directly available to tissues. Because of this distribution, total serum B12 partly reflects the haptocorrin-bound reservoir, which is one reason the biologically active fraction is measured separately.

The liver is the principal storage organ. It holds the largest share of the body's B12, which is typically several milligrams in total, far more than the small daily requirement of a few micrograms. Biliary excretion sends B12 into the intestine, but much of it is reabsorbed through enterohepatic recirculation, which conserves the body's supply. Because of these reserves, depletion after intake stops generally takes years, often several, before deficiency becomes evident. The same recycling loop still depends on intrinsic factor, so a defect in absorption can continue to cause losses even while stores remain in place.

Dietary sources and microbial synthesis

Cobalamin is made only by a restricted group of organisms: it is synthesized only by certain bacteria and archaea, not by plants. Within the wider living world, the biosynthetic pathway is missing from fungi, plants and animals, so every B12 molecule in the food chain traces back to bacteria or archaea. Microbes that live in the colon add to this supply, but people cannot use it there. Vitamin B12-producing bacteria colonize the large bowel, but humans cannot absorb bacterial vitamin B12 from the large intestine, so the colonic supply does not contribute to human nutrition.

The main route into the human diet runs through animals. Ruminants such as cattle and sheep depend on microbes in their stomachs, and the vitamin they obtain collects in their tissues and milk. The meat and milk of herbivorous ruminants, such as cattle and sheep, are good sources of vitamin B12 for humans. Among animal foods, offal ranks highest. The richest food sources include meat, especially liver, followed by kidney and heart, along with eggs, dairy products, fish and shellfish. In meat and fish, adenosylcobalamin and hydroxocobalamin make up most of the vitamin present.

Plant foods are a poor source. Plants do not contain vitamin B12, except for some dried green and purple seaweeds, which have a symbiotic relation with B12-producing bacteria. Because the principal sources are animal products, people who avoid them face a supply problem. One UK study found that UK vegans consuming typical vegan diets had dietary intakes considerably lower than recommended, at only 0.5 ± 0.08 µg/day, approximately 10% of the B12 intake in the average UK diet. Dietetic bodies respond by advising reliable sources. The Academy of Nutrition and Dietetics' vegetarian group says all vegetarians, including vegans, should include a reliable B12 source in their diets, such as fortified foods or supplements. Fortified products such as nutritional yeast and breakfast cereals are common carriers in these diets.

Commercial cobalamin is produced by microbial fermentation rather than by chemistry. Chemical synthesis involves approximately 70 stages and is costly, so industrial production relies entirely on fermentation with microorganisms, typically P. denitrificans. Large-scale industrial production predominantly uses Pseudomonas denitrificans, Propionibacterium shermanii, or Sinorhizobium meliloti. Optimized processes can be very productive; for example, Pseudomonas denitrificans strains can be used to produce up to 200 mg/L of B12 under biotechnological conditions. The fermentation product is then converted into the form that dominates commerce. The most common commercial form of vitamin B12 is cyanocobalamin, a more stable form that the body readily converts into active coenzyme forms. That final conversion uses chemical conversion and purification steps that are expensive, unsafe for operators and environmentally unfriendly. Fermentation-derived material then feeds pharmaceuticals, food fortification and animal feed.

Discovery and history

Pernicious anemia was recognized as a clinical disease in the mid-nineteenth century. Pernicious anemia was recognized clinically in the mid-19th century by Addison, but the most important neurological manifestation - subacute combined degeneration of the spinal cord - was not recognized clinically and linked with pernicious anemia until the end of the 19th century, particularly by Lichtheim, Putnam, and Dana. The term itself was coined in 1872 by Biermer, who suspected that the disorder was connected with a disease of the stomach. Until the 1920s, it was usually fatal, and no effective therapy existed.

The first therapeutic lead came from unrelated research. In 1925, George Whipple published a series of papers in which he demonstrated that raw liver fed to anaemic dogs was the most effective diet for reversing anaemia and boosting the production of red blood cells. Whipple's dogs had been made anemic by blood loss, so the finding concerned red-cell regeneration rather than the disease in humans. George Minot and William Murphy then tested liver in patients. After oral administration of liver (45-50 g per day) for 45 patients with anaemia perniciosa improvement of the hematological status was demonstrated. Their 1926 report established liver as an effective treatment, and Whipple, Minot, and Murphy were subsequently recognized jointly with the 1934 Nobel Prize in Physiology or Medicine for this work. Because large amounts of liver had to be eaten, the treatment was cumbersome. In 1928, Edwin Cohn produced a liver extract that was 50-100 times more potent than liver itself, and the extract could be injected, which was a great improvement on the previous treatment of eating large quantities of liver.

The question of what in liver was active then moved to the stomach. Beginning in 1929, William Bosworth Castle proposed that two factors were needed. Castle postulated that extrinsic and intrinsic factors were required to absorb the antipernicious anemia factor present in liver tissue. The gastric secretion he named intrinsic factor, which was necessary for the absorption of a dietary "extrinsic factor." That extrinsic factor is what later became known as vitamin B12, the product of intrinsic factor research, a link that remains central to the disease's pathology.

The vitamin itself was isolated in 1948. A red crystalline substance having the clinical activity of liver and designated as vitamin B12 was isolated almost simultaneously by two independent groups led by Folkers (Merck Company, USA) and E.L. Smith (Glaxo Company, UK). The two teams used different assays to guide their work. The success of Folkers' group was largely attributable to a microbiological assay developed by Shorb in 1947; Smith used the human bioassay procedure. The structure followed in the mid-1950s. The complicated structure of vitamin B12 was established by Hodgkin using X-ray crystallography in 1955. Her work was later recognized by the 1964 Nobel Prize in Chemistry.

Only after the isolation did researchers turn to how the vitamin works inside cells. Its enzymatic roles were mapped in the decades that followed, including its close link with folate metabolism, which explained why deficiency of either nutrient produces similar blood changes. The discovery sequence thus ran from clinical observation, to a dietary remedy, to a gastric factor, and finally to a pure chemical compound.

Causes of deficiency

Vitamin B12 deficiency arises through four broad routes: inadequate dietary intake, poor bioavailability, malabsorption, and disrupted transport or cellular uptake. The distinction matters clinically. A dietary shortfall can often be corrected by changing what a person eats or by supplementation, whereas an absorption defect may require parenteral replacement.

Inadequate intake and bioavailability

Because humans cannot make the vitamin, they depend on food, and diets that exclude animal products carry the greatest risk. Strict vegan diets without supplementation are the clearest example, and breastfed infants of vegan mothers can be affected as well. Fad diets with severe restriction have the same effect. Even when intake is adequate, B12 must first be freed from food proteins by gastric acid and digestive enzymes, so conditions that reduce stomach acid can lower the amount that is available for absorption. Reduced acid secretion is common in older adults.

Malabsorption

Pernicious anemia is the classic malabsorptive cause. In this autoimmune disorder, antibodies attack either intrinsic factor itself or the parietal cells that secrete it, so the vitamin cannot be carried to its absorption site in the terminal ileum. The condition is strongly associated with other autoimmune diseases and with a family history of autoimmunity, and it is a leading cause of deficiency in developed countries, particularly among older adults. Patients with classic pernicious anemia, most often younger adults, also face an increased risk of stomach and other gastrointestinal cancers. The loss of acid-secreting and intrinsic-factor-producing cells can also follow from atrophic gastritis caused by ageing or by Helicobacter pylori infection.

Several other conditions impair absorption in similar ways. Gastric bypass surgery and partial gastrectomy remove the tissue that produces intrinsic factor and acid. Disease of the small intestine, including Crohn's disease, coeliac disease, and surgical removal of the ileum, damages the site where the vitamin is taken up. Some parasitic infections, such as fish tapeworm infestation, and bacterial overgrowth in a blind loop compete for the vitamin in the gut. Advanced HIV infection and chronic pancreatic disease have also been linked to poor absorption. Certain medications, including metformin, proton pump inhibitors, and H2-receptor antagonists, may reduce uptake. Pharmacological reviews note, however, that such drugs rarely cause symptomatic deficiency, because they are seldom taken long enough to exhaust the body's stores.

Transport and cellular uptake

Once absorbed, B12 is carried in the blood by transport proteins, and a defect in this system can produce deficiency even when intake and absorption are normal. Inherited transcobalamin II deficiency is a genetic mutation that impairs delivery of the vitamin to tissues, and it usually becomes apparent in infancy. A rare inherited ileal malabsorption disorder, Imerslund-Grasbeck syndrome, similarly presents early in life. Defects in the enzymes that use the vitamin, along with liver disorders, can also reduce utilization.

Nitrous oxide and other associated conditions

Nitrous oxide, the anaesthetic gas commonly known as laughing gas, is a distinctive cause because it acts directly on the vitamin. When the gas reaches high concentrations, it oxidises the cobalt centre of the cofactor into an inactive form that the body's enzymes cannot use. Recreational abuse can precipitate deficiency in otherwise healthy people, but case reports also describe deficiency emerging in previously asymptomatic individuals after only brief exposure during dental or surgical procedures, which suggests that undiagnosed underlying deficiency may be a contributing factor.

Lower serum B12 concentrations have also been reported in pregnancy and in people treated with anticonvulsant drugs for epilepsy. These findings describe reduced circulating levels, and they do not on their own establish that clinical deficiency is present.

Clinical manifestations

Vitamin B12 deficiency tends to declare itself through the blood-forming system, the nervous system, or both, and the two sets of signs do not always move together. Blood-related changes can be absent even when nerve damage is severe, and in one large series the degree of neurological impairment was inversely related to the degree of anemia. The clinical picture therefore has to be read as a spectrum rather than a single syndrome.

Hematological effects

The blood changes are those of megaloblastic anemia. Red cells become enlarged, so the mean corpuscular volume rises, and the nuclei of neutrophils show hypersegmentation. Neutropenia and megaloblastic changes in the bone marrow may also appear. Peripheral blood findings are, however, a poor guide to severity: they can stay near normal in people with significant neurological disease. Symptoms of severe anemia include fatigue, breathlessness on exertion, and chest discomfort. When anemia is profound, the heart can be strained, producing features that resemble congestive heart failure, such as ankle swelling, breathlessness when lying flat, and nocturnal urination. Less specific features reported in pernicious anemia include excessive weight loss and a sore tongue, while glossitis itself is described as uncommon. Splenomegaly or hepatomegaly occasionally occurs. Because the decline is slow, the body often adapts, and the degree of illness can exceed what the patient reports.

Neurological and neuropsychiatric effects

The best-characterised neurological syndrome is subacute combined degeneration of the spinal cord. It involves demyelination of the posterior and lateral columns, most often in the cervical and thoracic segments, and produces symmetrical disturbances of sensation, impaired joint position sense, and spastic weakness in the legs or all four limbs. On magnetic resonance imaging it appears as symmetrical signal change in the affected columns. Early in the course, reduced vibration and position sense occur alongside mild weakness and diminished reflexes; later, spasticity, an extensor plantar response, and ataxia may develop. Damage to the peripheral nerves can be demyelinating or axonal, typically producing tingling, numbness, and a pins-and-needles sensation, most noticeable in the feet. Optic nerve involvement is less common. These neurological effects can arise without anemia; case reports describe patients with significant spinal or peripheral nerve disease and a blood count in the normal range.

Neuropsychiatric symptoms can appear before any hematological sign. Reported features include memory impairment, difficulty with attention, and dementia, and cognitive complaints may be the first presentation. In infants, deficiency has been associated with irritability, reduced muscle tone, poor feeding, and developmental delay, and a case report of an exclusively breastfed infant described lasting psychomotor retardation attributed to a delayed diagnosis.

Mild and moderate presentations

Mild deficiency is frequently asymptomatic and may be found only through laboratory testing. Moderate deficiency is more likely to produce a nonspecific cluster of complaints: tiredness, mouth ulcers, digestive disturbance, and abnormal sensations in the limbs. Because these features overlap with many other conditions, they rarely point to vitamin B12 on their own. This is one reason why laboratory biomarkers and clinical diagnosis are used together, and why the neurological and hematological findings described above are considered in the differential diagnosis of unexplained fatigue, gait disturbance, or cognitive decline.

Diagnosis and biomarkers

Vitamin B12 status is most often assessed by measuring total cobalamin in serum or plasma. This assay counts all circulating forms of the vitamin, including forms that cells cannot use, so a normal result does not always mean that tissues are adequately supplied. Cut-offs also differ by method and laboratory. Current practice generally treats concentrations below 148 pmol/L as deficient, values between 148 and 221 pmol/L as marginal, and levels above 221 pmol/L as adequate in adults. Many laboratories still use 200 pmol/L as the threshold for subnormal values. Because total B12 has limited sensitivity for metabolic deficiency, clinicians usually add other tests.

The most specific of these is holotranscobalamin, the fraction of B12 bound to transcobalamin II, the carrier protein that delivers the vitamin into cells. Its concentration falls when cellular supply declines, which makes it an early indicator. Published cut-offs range widely, from about 20 to 50 pmol/L. In one multicentre study, a threshold of 32 pmol/L gave the highest sensitivity for detecting metabolic deficiency, defined as methylmalonic acid above 0.45 μmol/L, though its specificity was only moderate.

Methylmalonic acid (MMA) and homocysteine are functional markers. They accumulate when the two B12-dependent enzymes lose activity: MMA rises when methylmalonyl-CoA mutase cannot convert its substrate to succinyl-CoA, and homocysteine rises when methionine synthase lacks methylcobalamin. Because they reflect enzyme performance rather than the amount of vitamin present, they can reveal deficiency that total B12 misses. Reported MMA cut-offs cluster between about 0.21 and 0.47 μmol/L, and the NIH fact sheet cites values above 0.271 μmol/L as suggestive of deficiency, with homocysteine above 15 μmol/L as a further indicator. Both markers are confounded. Reduced kidney function raises MMA and homocysteine, MMA tends to be higher in older adults, and homocysteine is affected by folate status. For this reason, interpretation requires renal function to be taken into account.

Some protocols combine these markers in sequence. One two-step algorithm, described in evidence reviews prepared for NICE, measures holotranscobalamin first and proceeds to MMA only when the result falls in an intermediate range of 25 to 70 pmol/L. MMA values below 280 nmol/L (360 nmol/L in patients over 65) are then taken to indicate sufficiency, while higher values suggest deficiency.

Subclinical deficiency is usually defined by total serum B12 below 200 pmol/L, though its definition varies with the method and with the markers used. Individuals in this state may have no symptoms, or their complaints, such as fatigue, numbness, or cognitive change, may resemble those of unrelated disorders, which makes attribution difficult. Total B12 can also be falsely low in conditions unrelated to nutrition, including multiple myeloma, haptocorrin deficiency, folate deficiency, and oral contraceptive use, and levels tend to fall during pregnancy. Marginal status is common in later life; one review noted that more than 20% of people over 60 fall into the marginal range. Because no single consensus cut-off exists, results are best read together with the clinical picture and with a measure of folate, since the two vitamins share metabolic pathways.

Epidemiology and risk groups

Estimates of how common vitamin B12 deficiency is depend heavily on the threshold and the population studied. One review of U.S. data puts deficiency at about 3% of adults aged 20–39, 4% of those aged 40–59, and 6% of those aged 60 and over. A more recent analysis of NHANES data from 2007–2018 gives a lower overall rate of about 3.6% for adults aged 19 and over, with 3.7% among those aged 60 and over, using a serum cut-off of 148 pmol/L. The same analysis found that insufficiency, defined at 221 pmol/L, reaches roughly 12.5% of adults, which shows how far the choice of threshold changes the picture. Earlier NHANES data from 1999–2004 illustrate the same point: prevalence ranged from 2.9% to 25.7% depending on whether a serum cut-off or the functional marker methylmalonic acid was used. Sex also appears to matter, with women showing higher rates than men in NHANES data.

Subclinical deficiency, in which blood levels are low but overt anemia or neurological signs are absent, is estimated to affect between 2.5% and 26% of the general population, depending on how it is defined. Its clinical consequences remain uncertain. Age is consistently associated with higher rates. In NHANES, about 6.9% of U.S. adults aged 51–70 and 15% of those over 70 were deficient. Among older people, prevalence is much higher in institutional settings: community-living elderly show roughly 4–5%, while people in care facilities with multiple comorbidities show around 30–40%. Deficiency can occur at any age, but it is most frequent in older individuals.

Several groups are recognized as being at elevated risk. Guidance from primary care sources lists people who have had gastric or small-intestine resection, those with inflammatory bowel disease, long-term users of metformin (beyond about four months) or of acid-suppressing drugs such as proton pump inhibitors and H2 blockers (beyond about a year), strict vegetarians and vegans, and adults over 75. Malabsorptive conditions, bariatric surgery, and certain medications such as metformin and antacids are each linked to substantially higher prevalence in clinical cohorts. In one study, U.S. adult vegetarians showed rates between 30% and 47%. Pregnancy lowers serum levels, which usually recover after delivery. Infants and children, and women of reproductive age, are also regarded as vulnerable where intake of animal-derived foods is restricted, a concern that is especially relevant to public health planning and to dietary policy.

Patients with cancer form another high-risk group. Reported prevalence estimates range from 6% to 48%, reflecting differences in population, age and definition. The highest rates have been observed among people with digestive-tract tumours and among older patients. Gastrointestinal surgery, malnutrition, liver metastases and chemotherapy all impair status. In one study, about 8% of patients with pancreatic cancer were deficient when they began systemic chemotherapy. Because these patients often have overlapping causes of anemia, interpreting biomarker results in oncology settings is difficult.

Not all abnormal results indicate low intake. Serum levels can be raised in people with renal failure, liver disease, and myeloproliferative disorders, so a high reading may reflect disease rather than abundant supply. Conversely, methylmalonic acid also rises with reduced kidney function, which complicates the interpretation of functional markers in older adults and in patients with kidney disease, and this is one reason why epidemiological estimates vary so widely between studies.

Treatment and clinical management

Cobalamin deficiency can be treated by parenteral injection or by high-dose oral dosing. The traditional regimen is intramuscular cyanocobalamin, commonly 1 mg given weekly for about eight weeks and then monthly for life, although UK services use intramuscular hydroxocobalamin and other loading schedules. Oral therapy has gained ground because very high doses can work even when intestinal absorption is impaired. A 2018 Cochrane review of three randomized trials (153 participants) found that doses of 1,000–2,000 µg by mouth normalized serum B12 about as well as injections, but the evidence was judged to be of low quality. The mechanism is passive diffusion: a small fraction of free cobalamin crosses the gut wall without intrinsic factor.

The two routes are not interchangeable in every setting. Injections are generally preferred at diagnosis when neurological symptoms are present or the deficiency is severe, and in corpus atrophic gastritis, where intrinsic factor production is lost and intramuscular dosing is recommended to bypass the absorption defect. Oral regimens are simpler, cheaper and avoid injection-site pain, but they depend heavily on adherence. In a Crohn's disease cohort, nonadherence accounted for most oral failures. Injections are rarely associated with serious reactions such as anaphylaxis, which clinicians are advised to watch for.

Folic acid must not be used as a substitute. It can correct the megaloblastic anemia of B12 deficiency, which means the anemia may disappear while neurological damage continues. The risk is greatest when the diagnosis rests on blood counts alone. A case report of optic neuropathy illustrates the point: a patient whose B12 deficiency was treated with oral B12 and folic acid developed progressive vision loss, and recovery followed parenteral B12 and only then folic acid. Where both deficiencies coexist, guidance generally advises starting cobalamin before adding folic acid. The hematological abnormalities respond to folate, but the neurological manifestations respond only to cobalamin, which is why parenteral replacement is recommended soon after a neurological deficiency is established.

Treatment also addresses the cause. Pernicious anemia, an autoimmune loss of intrinsic factor, usually requires lifelong replacement because the defect is not reversible. Dietary deficiency, by contrast, may respond to over-the-counter oral cyanocobalamin, methylcobalamin or adenosylcobalamin, and some guidelines describe a fixed course of a few months, with supplementation reviewed once intake and exposure are corrected. Other causes, including gastric surgery, ileal disease or drug-induced malabsorption, require management of the underlying condition alongside replacement.

Response is followed on two levels. Hematological recovery, such as a rise in reticulocytes and improvement in hemoglobin and mean corpuscular volume, shows that blood cell production is restoring. Biochemical recovery is judged by the normalization of biomarkers such as serum B12, holotranscobalamin and methylmalonic acid. Neurological improvement is slower and less predictable than blood-count recovery, so clinicians rely on repeated clinical assessment rather than laboratory values alone.

Research frontiers and open questions

Diagnostic thresholds

Clinicians still lack agreed cut-offs for B12 status. A review of published criteria found no consensus on the cut-off points for vitamin B12 and its co-markers, such as folate, holotranscobalamin, methylmalonic acid and homocysteine. The spread is wide: vitamin B12 ranged between 100 pmol/L and 350 pmol/L, holotranscobalamin 20-50 pmol/L, methylmalonic acid 0.210-0.470 μmol/L. Even the upper limit for methylmalonic acid is disputed, and reported values vary from 0.26 µmol/L to 0.40 µmol/L, and these limits have been derived from B12 replete populations and may be an ideal rather than normal range.

Holotranscobalamin (holoTC) has attracted interest as an earlier indicator, but its own thresholds vary. One multicentre study proposed a cut-off value of 32 pmol/L of holoTC for detecting elevated methylmalonic acid, a choice that trades sensitivity against specificity. Reference intervals also differ by population: in pregnant women, the lower limits of total B-12 and holoTC and the upper limits of MMA significantly differed by ethnicity in both trimesters. Whether the more sensitive markers actually change outcomes remains open. Some studies report that measurements of MMA, holotranscobalamin, and homocysteine levels were not superior to the measurement of total vitamin B12 levels, so the clinical meaning of subclinical deficiency is still unsettled.

Thymidylate synthesis and genome stability

The most active mechanistic question concerns DNA integrity. When B12 is limited, folate becomes increasingly trapped in the 5-methyl-THF form, which decreases the availability of other folate cofactors for nucleotide synthesis. A 2017 study in cultured cells argued that this trap operates inside the nucleus as well: vitamin B12 depletion decreased de novo dTMP biosynthesis capacity by 5–35%, whereas de novo purine synthesis, which occurs in the cytosol, was not affected. Because thymidylate is needed to build the "T" base of DNA, DNA polymerases incorrectly incorporate a uracil (or "U") base into DNA when dTTP levels are low, which can destabilise the genome.

Downstream evidence links these disturbances to chromosomal damage. Reviews of folate and B12 deficiency describe increased micronucleus formation in vivo, and intervention data suggest that micronucleus formation is minimised when plasma concentration of vitamin B12 is greater than 300 pmol/L. These findings should be read with caution: much of the mechanistic work uses cell lines and genetically modified fibroblasts, and extending it to whole-body human disease is not yet established.

Cancer populations

Vitamin B12 status is being studied in relation to cancer-related anaemia and to neuropathy induced by chemotherapy, where the link to nerve damage and to the overall treatment burden is still being characterised. Interest is also growing in whether B12 influences immune function in the context of cancer therapy, including immunotherapy; this remains an emerging area, and the evidence base is currently small.

Helicobacter pylori, autoimmune gastritis and pernicious anaemia

The relationship between Helicobacter pylori infection and autoimmune gastritis is one of the most contested questions in this field. A systematic review reported a higher prevalence of H. pylori infection in pernicious anemia patients, with some studies suggesting a consequential increase in the aforementioned antibodies. Other data point the other way. In a cohort of Japanese patients, the researchers concluded that there are conflicting views about the association between type A gastritis with pernicious anemia (PA) and infection with Helicobacter pylori, and currently, no definite conclusion has been reached. Clinical reviews likewise note that autoimmune body gastritis is generally considered a separate entity from H pylori-related atrophic gastritis, mainly because the prevalence of H pylori infection in patients with severe ABG and PA has been found to be low.

A proposed mechanism is molecular mimicry: activated CD4+ Th1 cells that infiltrate the gastric mucosa cross-recognize the epitopes of self gastric parietal cell H+K+-ATPase and of various H. pylori proteins. In that model, infection could trigger disease in genetically susceptible people. Some treatment data are encouraging, as eradication of H. pylori displayed potential therapeutic effects; patients showcased reductions in antibody titers, but the authors of that review also stressed that disparities across studies make direct comparisons challenging. Whether H. pylori is a cause, a cofactor or an incidental finding in pernicious anaemia has yet to be resolved.

References

1. Genetic disorders of vitamin B12 metabolism: eight complementation groupscambridge.org
2. Vitamin B12chm.bris.ac.uk
3. Vitamin B₁₂: Cobalamin - Chemistry LibreTextschem.libretexts.org
4. Biological properties of vitamin B12cambridge.org
5. Cyanocobalamin - an overviewsciencedirect.com
6. Radionuclide labeling of vitamin B.sub.12 and coenzymes thereofimage-ppubs.uspto.gov
7. Radionuclide labeling of vitamin B12 and coenzymes thereofimage-ppubs.uspto.gov
8. Human B12-dependent enzymes: Methionine synthase and Methylmalonyl-CoA mutase - PubMedpubmed.ncbi.nlm.nih.gov
9. Human B12-dependent enzymes: Methionine synthase and Methylmalonyl-CoA mutase - ScienceDirectsciencedirect.com
10. Vitamin B12 Metabolism during Pregnancy and in Embryonic Mouse Modelsncbi.nlm.nih.gov
11. Vitamin B12 Biochemistry and (Patho)-Physiologyencyclopedia.pub
12. Vitamin B12 sources and microbial interaction - Fumio Watanabe, Tomohiro Bito, 2018journals.sagepub.com
13. Nutritional assessment - Vitamin B12nutritionalassessment.org
14. The importance of vitamin B12 for individuals choosing plant-based diets - PMCpmc.ncbi.nlm.nih.gov
15. Vitamin B12 and the Vegan Diet - Today's Dietitian Magazinetodaysdietitian.com
16. Propionibacterium spp.—source of propionic acid, vitamin B12, and other metabolites important for the industrylink.springer.com
17. Microbial production of vitamin B12: a review and future perspectives - PMCpmc.ncbi.nlm.nih.gov
18. Industrial vitamin B12 production by Pseudomonas denitrificans using maltose syrup and corn steep liquor as the cost-effective fermentation substratesresearchgate.net
19. Production and use of compositions comprising high concentrations of vitamin B12 activityimage-ppubs.uspto.gov
20. Vitamin B12 - an overviewsciencedirect.com
21. Vitamin B12 • The Nutrition Sourcenutritionsource.hsph.harvard.edu
22. Chapter 30: historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins - PubMedpubmed.ncbi.nlm.nih.gov
23. One History of Pernicious Anaemiapernicious-anaemia-society.org
24. [History of the therapy of pernicious anemia] - PubMedpubmed.ncbi.nlm.nih.gov
25. Pernicious Anemia - an overviewsciencedirect.com
26. The discovery of Pernicious anaemiaanimalresearch.info
27. Vitamin B12link.springer.com
28. Chapter 30 Historical aspects of the major neurological vitamin deficiency disorders: the water-soluble B vitamins - ScienceDirectsciencedirect.com
29. William Bosworth Castleen.wikipedia.org
30. Vitamin B12 Deficiency - Nutrition - Merck Manual Professional Editionmerckmanuals.com
31. Vitamin B12 Deficiency - Nutrition - Merck Manual Consumer Versionmerckmanuals.com
32. Vitamin B12 Deficiency Anemia: Symptoms, Causes, Treatmentswebmd.com
33. Reversible nitrous oxide–induced myeloneuropathy with pernicious anemia: Case report and literature review - Singer - 2008 - Muscle & Nerve - Wiley Online Libraryonlinelibrary.wiley.com
34. Subacute Combined Degeneration Secondary to Nitrous Oxide Abuse: Quantification of Use With Patient Follow-upncbi.nlm.nih.gov
35. Vitamin B12 Deficiency and Pernicious Anaemiapernicious-anaemia-society.org
36. Unmasking Pernicious Anemia: A Reversible Cause of Pancytopenia Due to Severe Vitamin B12 Deficiencyncbi.nlm.nih.gov
37. Pernicious Anemia: Background, Pathophysiology, Etiologyemedicine.medscape.com
38. Cobalamin Deficiency: Clinical Picture and Radiological Findingsncbi.nlm.nih.gov
39. Vitamin B12 deficiencymedlink.com
40. Vitamin B12 deficiency - Knowledge @ AMBOSSamboss.com
41. B12 deficiency with neurological manifestations in the absence of anaemiancbi.nlm.nih.gov
42. Vitamin B12 deficiency as a cause of severe neurological symptoms in breast fed infant – a case reportncbi.nlm.nih.gov
43. Vitamin B12 in Cancer Patients: Clinical Insights into Deficiency, Excess, Diagnosis, and Managementncbi.nlm.nih.gov
44. Vitamin B12 - Health Professional Fact Sheetods.od.nih.gov
45. The Revised D‐A‐CH‐Reference Values for the Intake of Vitamin B12: Prevention of Deficiency and Beyond - PMCpmc.ncbi.nlm.nih.gov
46. Vitamin B12 deficiency - PMCpmc.ncbi.nlm.nih.gov
47. Screening for metabolic vitamin B12 deficiency by holotranscobalamin in patients suspected of vitamin B12 deficiency: a multicentre study - PubMedpubmed.ncbi.nlm.nih.gov
48. A review of the cut-off points for the diagnosis of vitamin B12 deficiency in the general population - PubMedpubmed.ncbi.nlm.nih.gov
49. FINAL Vitamin B12 deficiency: evidence reviews for ...ncbi.nlm.nih.gov
50. Full article: Vitamin B12 status in health and disease: a critical review. Diagnosis of deficiency and insufficiencytandfonline.com
51. How common is vitamin B-12 deficiency? - ScienceDirectsciencedirect.com
52. Vitamin B12 deficiencypmc.ncbi.nlm.nih.gov
53. Vitamin B12 deficiencynature.com
54. Vitamin B12 deficiency - bevitalbevital.no
55. Vitamin B12 Deficiency: Recognition and Managementaafp.org
56. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut. ...frontiersin.org
57. Prevalence and Indicators of Vitamin B12 Insufficiency among Young Women of Childbearing Age - PMCpmc.ncbi.nlm.nih.gov
58. Subclinical B12 Deficiency in Elderlyencyclopedia.pub
59. Perspective: Practical Approach to Preventing Subclinical B12 Deficiency in Elderly Population - PMCpmc.ncbi.nlm.nih.gov
60. Vitamin B12 in Cancer Patients: Clinical Insights into Deficiency, Excess, Diagnosis, and Managementmdpi.com
61. 2108P Vitamin B12 and its clinical relevance in hospitalized cancer patients - Annals of Oncologyannalsofoncology.org
62. Oral Cyanocobalamin is Effective in the Treatment of Vitamin B12 Deficiency in Crohn’s Diseasencbi.nlm.nih.gov
63. Oral vs. Intramuscular Vitamin B12 in Vitamin B12 Deficiency • The Blood Projectthebloodproject.com
64. Anaphylactic Reaction to Cyanocobalamin: A Case Reportncbi.nlm.nih.gov
65. Guideline for the management of Vitamin B12 (Cobalamin) ...nwknowledgenow.nhs.uk
66. Intramuscular Cyanocobalamin Treatment in Patients with Corpus Atrophic Gastritis and Vitamin B12 Deficiency: Efficacy and Predictors of Increased Requirement—A Monocentric Longitudinal Real-Life Cohort Studyncbi.nlm.nih.gov
67. Vitamin B12 Management In Adultsnottsapc.nhs.uk
68. Vitamin B12 Deficiency Optic Neuropathyjournal.opted.org
69. Vitamin B12-Associated Neurological Diseases Medication: Dietary supplementsemedicine.medscape.com
70. Folic acid with or without vitamin B12 for cognition and dementia - PubMedpubmed.ncbi.nlm.nih.gov
71. Evaluation of a New Sublingual Methylcobalamin Dosage Regimen for Childhood Vitamin B12 Deficiencyncbi.nlm.nih.gov
72. (PDF) The limited value of methylmalonic acid, homocysteine and holotranscobalamin in the diagnosis of early B12 deficiencyresearchgate.net
73. Reference intervals for serum total vitamin B12 and holotranscobalamin concentrations and their change points with methylmalonic acid concentration to assess vitamin B12 status during early and mid-pregnancydoi.org
74. Reduced methionine synthase (*Mtr*) expression creates a functional vitamin B12 deficiency that leads to uracil accumulation in mouse mitochondrial DNAbiorxiv.org
75. Folate rescues vitamin B12 depletion-induced inhibitionpnas.org
76. Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity - ScienceDirectsciencedirect.com
77. Exploring the Association of Helicobacter pylori With Anti-intrinsic Factor and Anti-parietal Cell Antibodies in Pernicious Anemia: A Systematic Reviewncbi.nlm.nih.gov
78. In Japanese patients with type A gastritis with pernicious anemia the condition is very poorly associated with Helicobacter pylori infection - ScienceDirectsciencedirect.com
79. Pernicious anemia: New insights from a gastroenterological point of view - PMCpmc.ncbi.nlm.nih.gov
80. Role of Helicobacter pylori infection in pernicious anaemia - ScienceDirectsciencedirect.com
81. Megaloblastic anaemia in vitamin B12 deficiencycambridge.org
82. Folate rescues vitamin B12 depletion-induced inhibition of nuclear thymidylate biosynthesis and genome instabilitypnas.org
83. Diagnostic Accuracy of Holotranscobalamin, Vitamin B12, Methylmalonic Acid, and Homocysteine in Detecting B12 Deficiency in a Large, Mixed Patient Populationncbi.nlm.nih.gov